10.6084/m9.figshare.c.3660389_D2.v1 Daniela Massihnia Daniela Massihnia Amir Avan Amir Avan Niccola Funel Niccola Funel Mina Maftouh Mina Maftouh Anne van Krieken Anne van Krieken Carlotta Granchi Carlotta Granchi Rajiv Raktoe Rajiv Raktoe Ugo Boggi Ugo Boggi Babette Aicher Babette Aicher Filippo Minutolo Filippo Minutolo Antonio Russo Antonio Russo Leticia Leon Leticia Leon Godefridus Peters Godefridus Peters Elisa Giovannetti Elisa Giovannetti Additional file 1: Figure S1. of Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer Springer Nature 2017 Pancreatic ductal adenocarcinoma Akt Synergism Gemcitabine 2017-01-06 05:00:00 Presentation https://springernature.figshare.com/articles/presentation/Additional_file_1_Figure_S1_of_Phospho-Akt_overexpression_is_prognostic_and_can_be_used_to_tailor_the_synergistic_interaction_of_Akt_inhibitors_with_gemcitabine_in_pancreatic_cancer/4529255 PFS curves according to phospho-Akt expression in radically-resected PDACs, showing that patients with high and “very high” phospho-Akt (right panel) had a significantly worse PFS. Figure S2. Growth inhibitory effects after MK-2206 exposure in LPC006 (72-hours). Figure S3. Growth inhibitory effects after 72 hours exposure to perifosine, gemcitabine or their combination at a fixed ratio based on IC50 values in CFPAC-1 and PANC-1 cells. On the X-axis the drug concentrations for the combination are referred to gemcitabine. Figure S4. Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 4-hour exposure, as determined by ELISA. Figure S5. A Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 24-hour exposure. B Phospho-Akt (threonine residue-308) expression, normalized to total Akt, after 24-hour exposure, as determined by ELISA. Figure S6. Expression of gemcitabine determinants in PANC-1 cells treated with perifosine, as determined by qRT-PCR. Dashed line, values in untreated samples. Figure S7. Wound-healing assay in CFPAC-1 and PANC-1 exposed to perifosine, gemcitabine or their combination (IC50 values, 24 hours). Figure S8. Wound-healing assay in LPC006 exposed to MK-2206, gemcitabine or to their combination (IC50 values, 24 hours). Figure S9. Annexin-V assay in LPC028 and LPC006. Figure S10: Modulation of caspase-3, caspase-6/-8/ and caspase-9 in CFPAC-1 and PANC-1, as determined by a specific fluorometric assay. Figure S11. Cell growth inhibition in LPC006 cells after 72-hour exposure to MK-2205, NVP-BEZ235 at IC50 values, together with DMSO or with the Glut1 inhibitor PGL13, at 30 μM. Points, or Columns, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls. (PPTX 328 kb)